Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report

Go Noguchi1*, Sohgo Tsutsumi1, Masato Yasui1, Shinji Ohtake2, Susumu Umemoto1, Noboru Nakaigawa2, Masahiro Yao2 and Takeshi Kishida1

Abstract

Background: The treatment of advanced or metastatic renal cell carcinoma (RCC) has drastically changed since the approval of immune checkpoint therapy. Nivolumab is a treatment option for patients with metastatic RCC, previously treated with targeted antiangiogenic therapy. The efficacy of nivolumab for patients with RCC was established by the Checkmate 025 clinical trial. Chromophobe RCC (CRCC) represents around 5% of RCC cases, but non-clear cell RCC (non-ccRCC) subtypes were excluded from the Checkmate 025 clinical trial. We report a case in which the use of nivolumab as the seventh-line therapy elicited a significant response in the treatment of metastatic CRCC with sarcomatoid differentiation.

Case presentation: We report a case of a 41-year-old woman with metastatic CRCC with sarcomatoid differentiation. She was treated with sunitinib, pazopanib, everolimus, sorafenib, axitinib, and temsirolimus, but treatment was discontinued because of disease progression or strong adverse events. Seventh-line treatment with nivolumab was initiated and significant clinical improvement was noted after 4 cycles. The treatment was well-tolerated with no significant side effects and the patient continues with nivolumab treatment at present.

Conclusions: Nivolumab may be an attractive treatment option for non-ccRCC patients with sarcomatoid differentiation that exhibited aggressive characteristics and poor prognosis. Further investigation is warranted.

Keywords: Non-clear renal cell carcinoma, Sarcomatoid differentiation, Immune-checkpoint inhibitor, Nivolumab

Background

The treatment of advanced or metastatic renal cell carcinoma (RCC) has been drastically changed by the approval of immune checkpoint therapy. Nivolumab, the fully humanized monoclonal immunoglobulin(Ig)-G4 programmed death 1 (PD-1) checkpoint inhibitor, is a treatment option for patients with metastatic RCC previously treated with targeted antiangiogenic therapy. The efficiency of nivolumab for patients with RCC was established by the Checkmate 025 clinical trial [1]. Chromophobe RCC (CRCC) represents a heterogeneous RCC subtype and comprises about 5% of cases of RCC, but non-clear cell subtypes including CRCC were excluded from the Checkmate 025 trial [1]. To date, only one case of CRCC successfully treated with nivolumab has been reported [2]. We present a case of a patient with CRCC with sarcomatoid differentiation who presented a positive response to nivolumab.

Case presentation

A 41-year-old woman with no medical or family history presented with an incidental right renal tumor. Computed tomography (CT) imaging revealed a 9.5-cm tumor with no evidence of metastatic disease. She underwent right nephrectomy in August 2011. Pathological assessment revealed CRCC with sarcomatoid differentiation.
differentiation, 10.5-cm in maximal diameter and nu-
clear grade 4 (Fuhrman grade). The pathological stage was T2bN0M0.

Recurrence first occurred in September 2012 with mul-
tiple lung masses revealed on CT imaging. In February
and August 2013, she underwent metastasectomy twice
for the bilateral lung tumors, but recurrence reappeared
in February 2014 with multiple lung masses and lung hilar
lymph nodes. The pathological result of the lung tumors
was also CRCC with sarcomatoid differentiation.

In January 2015, she initiated first-line sunitinib on the
2/1 schedule (37.5 mg once daily for 2 consecutive
weeks on treatment followed by 1-week-off), but a drug
eruption appeared and the treatment with sunitinib was
discontinued. In February 2015, she initiated second-line
treatment with pazopanib, 800 mg daily, but the first
tumor assessment showed progression of disease. In
March 2015, third-line treatment with everolimus was
administered, but the disease progressed. In July 2015,
fourth-line treatment with sorafenib was administered,
but a drug eruption appeared. In September 2015, fifth-
line treatment with axitinib was administered, but the
disease progressed. In May 2016, sixth-line treatment
with temsirolimus was administered, but again, the dis-
ease progressed. Her performance status was declining
and the symptom of hoarseness from a recurrent nerve
paralysis was developing. In July 2016, she decided to re-
cieve best supportive care.

In October 2016, nivolumab was approved by pharma-
ceutical and medical devices agencies in Japan. She initi-
ated seventh-line treatment with nivolumab, 3 mg/kg
every 2 weeks, in October 2016. After 4 cycles, a partial
response was observed and the symptom of hoarseness
was not observed. Significant clinical improvement was
noted after 12 cycles (Fig. 1). The treatment has been
well-tolerated with no significant side effects thus far,
and the patient continues with the treatment of nivolu-
mab at present.

Discussion
RCC includes multiple histological subtypes. The most
common subtype is clear cell RCC (ccRCC) (80.5%),
followed by papillary RCC (PRCC) (14.3%), and CRCC
(5.2%) [3]. Several reports have suggested that localized
non-ccRCC is more likely to have a favorable prognosis
than that of ccRCC. Paradoxically, some series have
shown that metastatic, non-ccRCC exhibits significantly
lower response rates for systemic treatment and poorer
median progression-free and overall survival than those
with ccRCC [4, 5].

Nivolumab is a fully human IgG4 PD-1 immune
checkpoint inhibitor antibody that selectively blocks the

---

Fig. 1 Computed tomography images demonstrate a decrease in the size of lung nodules, lung hilar lymph node metastases, and skin metastases after four and twelve cycles of nivolumab. **a** Before initiating nivolumab therapy. **b** After four cycles of nivolumab. **c** After twelve cycles of nivolumab.
interaction between PD-1 and PD-1 ligands 1 (PD-L1) and 2 [1]. In the CheckMate 025 clinical trial, Motzer et al. suggested a superior response rate with nivolumab versus everolimus (25% vs. 5%, respectively) and longer median overall survival (25.0 months vs. 19.6 months, respectively) [1]. However, non-ccRCC patients were excluded in this study, and no prospective trials on the efficacy of immunotherapy in non-ccRCC have been published previously. Little is known about the efficacy of nivolumab in non-ccRCC. Here, we reported, to the best of our knowledge, the second case of a partial response to nivolumab achieved in a CRCC patient.

Only a few case reports have discussed non-ccRCC treated with immune-checkpoint inhibitors. Rouvinov et al. published the first case report on a CRCC patient with sarcomatoid transformation who exhibited a dramatic response to nivolumab as second-line therapy [2]. Geynisman reported the case of a patient with PRCC with sarcomatoid and rhabdoid features who exhibited an excellent response to nivolumab as third-line therapy [6]. Adra et al. reported the case of a patient with unclassified RCC with sarcomatoid features who demonstrated a significant response to nivolumab as second-line therapy [7].

Sarcomatoid differentiation is expressed in 5.1% of ccRCC and 8.2% of CRCC [3]. It has been reported that the presence of sarcomatoid histologic features in RCC is associated with significantly poor prognosis and outcomes for targeted therapies [8, 9]. On the other hand, Joseph et al. reported that PD-L1 positivity in RCC with sarcomatoid differentiation is detected in 89% of patients with these tumors and they may be good candidates for treatment with anti-PD-1/PD-L1 therapy [9]. It has been reported that PD-L1 expression is detected in 23.9% of ccRCC patients [10] and in 10.9% of non-ccRCC patients (5.6% in CRCC, 10% in PRCC, 30% in Xp11.2 translocation RCC, and 20% in collecting duct carcinoma) [4]; PD-L1 expression in RCC with sarcomatoid differentiation is extremely high.

Although PD-L1 expression is predictive of the response to PD-L1/PD-1 inhibitors in patients with lung cancer and melanoma, this association was not established in patients with ccRCC in the CheckMate 025 trial [1, 11, 12]. However, it is unclear whether PD-L1 expression may be a predictive marker for response to immune checkpoint therapy in patients with non-ccRCC. It has been reported that rapidly growing tumors are very likely to respond to anti-PD-1/PD-L1 therapy; although this is opposite to what has been observed previously in the era of molecular targeted therapy [13], there is a possibility that the prognostic factors established thus far may change greatly. The existence of sarcomatoid differentiation may be a predictive marker for the efficiency of nivolumab in non-ccRCC in the era of immuno-oncology. For patients with non-ccRCC with sarcomatoid differentiation that exhibit aggressive characteristics and poor prognosis, nivolumab may be an effective treatment.

Conclusions
We have reported a case of a metastatic CRCC with sarcomatoid differentiation treated with nivolumab as 7th-line therapy with a significant response. Sarcomatoid differentiation may be a predictive marker of the efficiency of nivolumab in patients with non-ccRCC and further investigation is warranted.

Abbreviations
RCC: Renal cell carcinoma; Ig: Immunoglobulin; ccRCC: Chromophobe RCC; Non-ccRCC: Non-clear cell RCC; PD-1: Programmed death 1; CT: Computed tomography; cRCC: Clear cell RCC; PRCC: Papillary RCC; PD-L1: PD-1 ligands 1

Acknowledgements
We would like to thank Editage (www.editage.jp) for English language editing.

Availability of data and materials
Due to ethical restrictions, the raw data underlying this paper is available upon request to the corresponding author.

Authors’ contributions
GN was responsible for the concept and drafted the manuscript. ST, MY1, SU and NN gave intellectual content and critically reviewed the manuscript. SO helped to provide patient history and helped in the writing of the manuscript. MY2 and TK treated the patient and helped to draft the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent for publication of their clinical details and clinical images was obtained from the patient.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 12 February 2018 Accepted: 10 April 2018

Published online: 18 April 2018

References
1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Pilmack ER, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.
2. Rouvinov K, Osyntsov L, Shaco-Levy R, Baram N, Ariad S, Memershain W. Rapid response to Nivolumab in a patient with sarcomatoid transformation of Chromophobe renal cell carcinoma. Clin Genitourin Cancer. 2017;15(6):e1127–30.
3. Leibovich BC, Loehse CM, Crispin PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;184(4):1309–15.
4. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albigeis L, Bellmunt J, Song J, Cano I, Lampron M, et al. PD-L1 expression in non-clear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178–84.
5. Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol. 2015;67(4):740–9.

6. Geynisman DM. Anti-programmed cell death protein 1 (PD-1) antibody Nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with Sarcomatoid and Rhabdoid features. Eur Urol. 2015;68(5):912–4.

7. Adra N, Cheng L, Pili R. Unclassified renal cell carcinoma with significant response to Nivolumab. Clin Genitourin Cancer. 2017;15(3):e517–9.

8. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2):235–41.

9. Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, Bryce AH, Vogelzang NJ, Stanton ML, Castle EP, et al. PD-1 and PD-L1 expression in renal cell carcinoma with Sarcomatoid differentiation. Cancer Immunol Res. 2015;3(12):1303–7.

10. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–5.

11. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–33.

12. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

13. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, et al. Hyperprogressive disease is a new pattern of progression in Cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1900–8.